Reed Jobs is betting on the end of cancer

Since its 2023 inception, Yosemite has evolved from a boutique experiment into a firm managing a portfolio of nearly 25 companies. The firm’s strategy rests on a hybrid model: using philanthropy to de-risk academic research in university labs before scaling successful concepts with venture capital. Jobs notes that the current landscape is shifting, as the industry faces a historic patent cliff and a surge in pharmaceutical cash reserves, creating a fertile environment for clinical innovation.

Central to this expansion is the integration of artificial intelligence, which Jobs views as a transformative tool for clinical trial design and drug discovery. By utilizing synthetic control arms and predictive modeling, he argues that researchers can bypass the most expensive bottlenecks in trial recruitment. The firm is currently targeting notoriously difficult genetic markers, including p53—a tumor suppressor gene often called the 'Achilles’ heel' of cancer—and the previously 'undruggable' KRAS mutation. While the firm has seen two scientific failures, Jobs remains firm on his 'open door' policy, prioritizing the viability of the science over the pedigree of the founder.